Management of Older Patients with Head and Neck Cancer: A Comprehensive Review

• Published in: Advances in therapy Vol. 40; no. 5; pp. 1957 - 1974
• Main Authors: Matos, Leandro L., Sanabria, Alvaro, Robbins, K. Thomas, Halmos, Gyorgy B., Strojan, Primož, Ng, Wai Tong, Takes, Robert P., Angelos, Peter, Piazza, Cesare, de Bree, Remco, Ronen, Ohad, Guntinas-Lichius, Orlando, Eisbruch, Avraham, Zafereo, Mark, Mäkitie, Antti A., Shaha, Ashok R., Coca-Pelaz, Andres, Rinaldo, Alessandra, Saba, Nabil F., Cohen, Oded, Lopez, Fernando, Rodrigo, Juan P., Silver, Carl E., Strandberg, Timo E., Kowalski, Luiz Paulo, Ferlito, Alfio
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.05.2023
• Subjects: Aged; Cardiology; Comorbidity; Endocrinology; Frailty - complications; Head and Neck Neoplasms - therapy; Humans; Internal Medicine; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Oncology; Pharmacology/Toxicology; Review; Rheumatology; Head and neck cancer; Prognosis; Treatment; Comorbidities; Complications; Old age
• ISSN: 0741-238X; 1865-8652; 1865-8652
• DOI: 10.1007/s12325-023-02460-x

The projected increase in life expectancy over the next few decades is expected to result in a rise in age-related diseases, including cancer. Head and neck cancer (HNC) is a worldwide health problem with high rates of morbidity and mortality. In this report, we have critically reviewed the literature reporting the management of older patients with HNC. Older adults are more prone to complications and toxicities secondary to HNC treatment, especially those patients who are frail or have comorbidities. Thus, this population should be screened prior to treatment for such predispositions to maximize medical management of comorbidities. Chronologic age itself is not a reason for choosing less intensive treatment for older HNC patients. Whenever possible, also older patients should be treated according to the best standard of care, as nonstandard approaches may result in increased treatment failure rates and mortality. The treatment plan is best established by a multidisciplinary tumor board with shared decision-making with patients and family. Treatment modifications should be considered for those patients who have severe comorbidities, evidence of frailty (low performance status), or low performance status or those who refuse the recommendations of the tumor board.